Vistagen Therapeutics, Inc. (VTGN)

Market Cap	193.53M
Revenue (ttm)	721,000
Net Income (ttm)	-62.24M
Shares Out	39.50M
EPS (ttm)	-1.92
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	544,577
Open	4.590
Previous Close	4.540
Day's Range	4.580 - 4.970
52-Week Range	1.900 - 5.140
Beta	0.57
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2025

About VTGN

Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company’s product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase II clinical trial to treat major depressive disorder. It also devel...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 57
• Stock Exchange: NASDAQ
• Ticker Symbol: VTGN
• Website: https://www.vistagen.com

Financial Performance

In 2024, Vistagen Therapeutics's revenue was $486,000, a decrease of -54.32% compared to the previous year's $1.06 million. Losses were -$51.42 million, 75.1% more than in 2023.